Physician

Ananda Walaliyadda, M.D.

According to 2025 Medicare claims, Ananda Walaliyadda, M.D. (NPI: 1497747703) practices rheumatology in the Idaho Falls, ID market, with the plurality of this provider's patient population coming from Bonneville, ID. This provider's primary affiliated billing organization is ARTHRITIS SPECIALTY CENTER,INC (NPI: 1801989454; TIN: 87-0705248) and primary practice location at 83442-5230. Walaliyadda is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Caravan Health ACO 50 LLC (ACO ID: A5160), MountainStar Care Partners ACO (ACO ID: A5181), Aledade 151 Northern Territories MSSP Enhanced (ACO ID: A5349), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Walaliyadda's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 596 traditional Medicare patients, billed 485,705 HCPCS/CPT codes, and received $4,491,211 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,484 prescription claims across 526 beneficiaries totaling $1,428,652 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 6 records totaling $133. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,238,289 to $4,491,211. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	626	181,763	$3,238,289
2016	628	155,273	$2,846,187
2017	617	241,542	$2,873,746
2018	642	212,305	$3,228,980
2019	663	242,856	$3,849,551
2020	615	275,171	$4,077,339
2021	666	285,898	$4,513,159
2022	646	330,394	$3,968,324
2023	608	408,032	$4,512,078
2024	596	485,705	$4,491,211

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	537	3,163	$2,731,530
2016	562	3,183	$2,790,254
2017	555	3,008	$2,822,460
2018	549	3,093	$3,641,167
2019	601	3,338	$4,954,047
2020	636	3,496	$5,233,663
2021	680	3,198	$5,298,719
2022	659	2,770	$5,161,251
2023	533	1,676	$2,234,998
2024	526	1,484	$1,428,652

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	334	1,526	$91
80053	Blood test, comprehensive group of blood chemicals	325	441	$10
36415	Insertion of needle into vein for collection of blood sample	367	527	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	358	498	$8
86140	Measurement c-reactive protein for detection of infection or inflammation	314	426	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	46	1,355	$372,426
Rinvoq	Upadacitinib	31	1,110	$237,832
Xeljanz Xr	Tofacitinib Citrate	15	450	$82,965
Kevzara	Sarilumab	14	392	$59,619
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	175	12,425	$7,044

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$133	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ananda Walaliyadda, M.D.?

Tedicare shows public-source Medicare data for Ananda Walaliyadda, M.D. (NPI 1497747703), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ananda Walaliyadda, M.D. have ACO affiliation data?

Ananda Walaliyadda, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), MountainStar Care Partners ACO (MSSP, ACO ID A5181), Aledade 151 Northern Territories MSSP Enhanced (MSSP, ACO ID A5349), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Ananda Walaliyadda, M.D.?

Ananda Walaliyadda, M.D. is linked to ARTHRITIS SPECIALTY CENTER,INC (billing NPI 1801989454) in the available physician profile data.

Does Ananda Walaliyadda, M.D. have Open Payments data?

Ananda Walaliyadda, M.D. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.